sec filings
Insider trades
Open-market buys and sales that company insiders report to the SEC on .
Side
Planned sales
Role
OTLK
Updated 10/6/2026, 1:28 PM ET.
| Stock | Side | Value | Insider | Shares | Avg price | Filed | Tags | Filing |
|---|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics, Inc. | Buy | n/a | Jahr Robert Charles Chief Executive Officer, Director | 151,515 sh | price n/a | Filed Aug 14, 8:57 PM ET | Filing | |
| OTLK Outlook Therapeutics, Inc. | Buy | $2,499,999 | Sukhtian Ghiath M. Director, 10% owner and 1 other | 2,525,252 sh | at $0.99 | Filed Aug 14, 7:52 PM ET | Filing | |
| OTLK Outlook Therapeutics, Inc. | Buy | n/a | KENYON LAWRENCE A Chief Financial Officer, Director | 101,010 sh | price n/a | Filed Aug 14, 7:39 PM ET | Filing | |
| OTLK Outlook Therapeutics, Inc. | Buy | $99,996 | Sukhtian Faisal Ghiath Director | 95,398 sh | at $1.05 | Filed Jul 29, 3:19 PM ET | Filing |